oncology

Obecabtagene Autoleucel Improves Survival in B-Cell Acute Leukemia

by

The Future of CAR T-Cell Therapy: Insights from the FELIX Study The FELIX study has marked a significant milestone in the treatment landscape of relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). With groundbreaking findings showing that patients achieving minimal residual disease–negative (MRD-negative) remission by next-generation sequencing (NGS) with obecabtagene autoleucel (Obe-Cel) enjoyed improved … Read more

2024 CSCO Breast Cancer guidelines revolutionize treatment approaches in China

by

The Evolution of Breast Cancer Treatment: Embracing Precision Medicine The landscape of breast cancer treatment is undergoing a remarkable transformation. Embracing the principles of precision medicine, recent guidelines, such as the 2024 Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines, are tailoring treatments to the unique molecular profiles of patients. This approach promises … Read more

Consistent Response, Durability Shown by Axatilimab Regardless of Prior Lines of Therapy in cGVHD

by

Exploring the Promising Future of Axatilimab in Chronic GVHD Treatment The approval of axatilimab for chronic graft-versus-host disease (cGVHD) marks a significant advancement in treatment options for patients whose conditions have been refractory to traditional therapies. This novel colony-stimulating factor 1 receptor (CSF-1R)-blocking antibody, known commercially as Niktimvo, presents new possibilities for personalized medicine. Let’s … Read more

Axatilimab Plus Ruxolitinib/Belumosudil May Yield Benefit in cGVHD

by

The Promising Future of Combination Therapies in Chronic Graft-vs-Host Disease The medical community has celebrated a significant breakthrough in the treatment of chronic graft-versus-host disease (cGVHD) with the emergence of combination therapies. A recent retrospective study presented at the 2025 Tandem Meeting highlighted the efficacy of using axatilimab-csfr (Niktimvo) in conjunction with ruxolitinib (Jakafi) and/or … Read more

Off-the-Shelf CAR-T Therapy P-BCMA-ALLO1 Shows Strong Activity in R/R Myeloma

by

Revolutionizing Cancer Treatment: P-BCMA-ALLO1 The medical world is abuzz over new advancements in cancer treatment, specifically with a new therapy called P-BCMA-ALLO1. This innovative chimeric antigen receptor (CAR) T-cell therapy is garnering attention thanks to its impressive results in a recent study. In this article, we delve into what makes P-BCMA-ALLO1 a game changer in … Read more

Post–PD-1 Data in Melanoma Offers Insight into IO Approaches

by

The Future of First-Line Immunotherapy in Melanoma Treatment As the demand for effective cancer therapies continues to rise, immunotherapy is leading the charge in providing hope for patients battling advanced melanoma. Understanding the Balance: Efficacy, Safety, and Quality of Life In striking the optimal balance between efficacy and patient safety, oncologists are facing new challenges … Read more

Anakinra Does Not Reduce CRS or ICANS in LBCL Treated With Liso-cel

by

Exploring the Efficacy of Anakinra in CAR T-Cell Therapy Toxicity Reduction The Phase 2 Revelation In a critical phase 2 trial, anakinra—a known IL-1 receptor antagonist—was tested for its potential to mitigate cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) in patients undergoing CAR T-cell therapy. Conducted with patients diagnosed with large … Read more

Huntsman Cancer Institute improves access for rural cancer patients

by

Bridging the Gap: How Mobile Healthcare is Reshaping Rural Cancer Care Thanks to initiatives like the federal contract awarded to Huntsman Cancer Institute, rural and frontier communities in Utah and beyond are seeing groundbreaking advancements in healthcare access. With innovative solutions like mobile medical vehicles and the Huntsman at HomeTM program, patients no longer need … Read more

USC receives $6 million grant for pioneering glioblastoma gene therapy

by

Revolutionary Gene Therapy: A New Horizon in Glioblastoma Treatment Glioblastoma, a formidable adversary in the realm of brain cancers, has long defied medical science, boasting a mere 5 percent five-year survival rate. Yet, hope is on the horizon, thanks to a groundbreaking gene therapy pioneered by researchers at the University of Southern California (USC). Recently … Read more

Tailoring CDS Tool Improves Biomarker Documentation in Cancer Treatment

by

Optimizing Clinical Decision Support Tools for Precision Medicine In the fast-evolving landscape of precision medicine, clinical decision support (CDS) tools are pivotal in aiding healthcare providers to make informed treatment decisions, especially in cancer care. A recent study led by Daniel Rubin, PharmD, BCOP at McKesson, signifies a significant stride in leveraging CDS tools for … Read more

© 2026 Newsy Today. All rights reserved.


For contact, advertising, copyright, issues email: [email protected]

For contact, advertising, copyright, issues email: [email protected]